Thursday, November 5, 2020
9:00-9:10 Opening Remarks, Stellar Abstract Awards
SESSION I: IDENTIFYING CAUSAL GENES AND PATHWAYS
Moderators: Bogdan Pasaniuc, Gosia Trynka
* last 5 minutes of all session talks reserved for questions and discussion
9:10-10:00
Danielle Posthuma | KEYNOTE SPEAKER
Vrije Universiteit (VU) University Amsterdam, Amsterdam University Medical Center
From GWAS to Function: Bridging the Gap Between Genetics and Neuroscience
10:00-10:35
Nicole Soranzo | Wellcome Sanger Institute
The allelic architecture of human disease risk factors
10:35-10:50
Olivia Corradin| Whitehead Institute
Identifying pathogenic cell types of individual disease alleles
10:50-11:20 BREAK
11:20-11:55
Dan Geschwind | UCLA School of Medicine
Annotation of chromatin structure and non-coding variation strongly implicates developing brain in neuropsychiatric disorders
11:55-12:30
Yoav Gilad | University of Chicago
Where Are the Disease-Associated eQTLs?
12:30-12:45
Huwenbo Shi | Harvard T.H. Chan School of Public Health
Enabling transcriptome-wide association studies at cell-type resolution
12:45-1:00 BREAK
SESSION II: FROM CAUSAL GENES AND PATHWAYS TO DRUG DISCOVERY AND PHARMACOGENETICS
Moderators: Xihong Lin, Kyle Vogan
1:00-1:50
Mark McCarthy | KEYNOTE SPEAKER
Genentech
Now we have 400+ Signals for Type 2 Diabetes Risk, What on Earth are we Going to Do with Them?
1:50-2:25
Cecilia Lindgren | Wellcome Trust Centre for Human Genetics
Machine Learning based histology phenotyping to investigate the epidemiologic and genetic basis of adipocyte morphology and cardiometabolic traits
2:25-3:00
Jeff Barrett | Wellcome Sanger Institute
Comprehensive genomic surveillance of SARS-CoV-2
3:00-3:30 BREAK
3:30-3:45
Mattia Cordioli | Institute for Molecular Medicine Finland, University of Helsinki, Finland
Genetic and environmental determinants of drug adherence and drug purchasing behaviour
3:45-4:20
Matt Nelson | Deerfield
Bending the drug R&D productivity curve with human genetics
4:20-4:35
Kumar Veerapen | MGH / Broad Institute
Assessing the Genetic Contribution of Drug Response Variability in Selective Serotonin Reuptake Inhibitors from 1,711,695 purchases in the Finnish National Drug Registry
4:35-6:00
Virtual Poster Session
Friday, November 6, 2020
SESSION III: POLYGENIC SCORES FOR DISEASE PREVENTION AND CLINICAL ACTION
Moderators: Eimear Kenny, Pete Kraft
9:00-9:50
Nilanjan Chatterjee | KEYNOTE SPEAKER
School of Medicine, Johns Hopkins University
Polygenic Risk Score: Development, Validation and Application
9:50-10:25
Lude Franke | University of Groningen
Reconciling germline and somatic variation through regulatory network integration
10:25-10:55 BREAK
10:55-11:10
Christopher Cassa | Brigham and Women’s Hospital, Harvard Medical School
Assessing clinical risk using polygenic risk and monogenic variants
11:10-11:45
Lisa Bastarache | Vanderbilt University
Polygenic and poly-phenomic approaches to disease prediction
11:45- 12:00
Burcu F. Darst | University of Southern California
Polygenic risk score developed in multiethnic prostate cancer GWAS meta-analysis and further investigated with metabolomics
12:00 – 12:35
Sek Kathiresan | Verve Therapeutics
From reading the genome for risk to rewriting for cardiovascular health
12:35-12:45 Closing Remarks
